California Public Employees Retirement System Trims Position in Regeneron Pharmaceuticals, Inc. $REGN

California Public Employees Retirement System lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 33.5% in the second quarter, Holdings Channel.com reports. The fund owned 314,716 shares of the biopharmaceutical company’s stock after selling 158,734 shares during the period. California Public Employees Retirement System’s holdings in Regeneron Pharmaceuticals were worth $165,226,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. PGGM Investments raised its stake in Regeneron Pharmaceuticals by 159.7% during the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock valued at $44,308,000 after buying an additional 51,900 shares during the last quarter. Founders Capital Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 7.0% during the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock valued at $4,344,000 after acquiring an additional 538 shares in the last quarter. Sepio Capital LP increased its holdings in shares of Regeneron Pharmaceuticals by 33.1% during the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock valued at $2,150,000 after acquiring an additional 842 shares in the last quarter. Generate Investment Management Ltd purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $6,300,000. Finally, Bellecapital International Ltd. boosted its stake in Regeneron Pharmaceuticals by 32.7% in the 2nd quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock worth $13,389,000 after purchasing an additional 6,283 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.6%

Shares of REGN stock opened at $718.36 on Monday. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $800.99. The stock has a market capitalization of $75.50 billion, a P/E ratio of 17.20, a P/E/G ratio of 2.06 and a beta of 0.37. The firm’s 50 day moving average is $650.69 and its 200 day moving average is $588.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the business earned $12.46 EPS. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were issued a $0.88 dividend. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

Insider Activity

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on REGN. Sanford C. Bernstein raised their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research note on Wednesday, August 27th. Wells Fargo & Company increased their price target on shares of Regeneron Pharmaceuticals from $615.00 to $700.00 and gave the company an “equal weight” rating in a report on Thursday, November 20th. Canaccord Genuity Group raised their price target on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research report on Thursday. Truist Financial initiated coverage on Regeneron Pharmaceuticals in a research report on Monday, November 24th. They issued a “buy” rating and a $798.00 price objective on the stock. Finally, HSBC initiated coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They issued a “buy” rating and a $255.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $777.36.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.